Research

Neurogene Doses First Participant in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Taysha Receives FDA Breakthrough Therapy Designation for TSHA-102

Hey Universe! Science + Serendipity at RSRT

Taysha Advances REVEAL Pivotal Trial for Rett Syndrome

Neurogene Announces Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Breaking Barriers: New Pathways Into the Brain

How Will Cuts to FDA and NIH Impact Gene Therapy Clinical Trials and Rett Syndrome Research?

Rewriting RNA: RSRT Funds Genetic Engineers in the AbuGoot Lab

3900 Trials and Counting: The Global Outlook on Genetic Medicines

Teaming Up With CRISPR Pioneer Jennifer Doudna to Develop Genetic Medicines for Rett

Updates from the MECP2 Editing Consortium

A Review of Gene Therapy Clinical Trials

ProQR and RSRT Expand Collaboration to Build on RNA Editing Momentum

Staying Resolute in Challenging Times

With Heavy Hearts

Neurogene Releases Update on NGN-401 Clinical Trial High Dose

A Tremendously Big Deal

Taysha Releases Financial, Enrollment Update and Community Letter